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Abstract 
In this multicentric, randomised, blinded and 
placebo-controlled field study, the effect of treat-
ment with toltrazuril (Baycox® Bovis, Bayer) on 
oocyst excretion, diarrhoea score and weight 
gain was studied in Danish dairy herds with 
confirmed history of eimeriosis (coccidiosis) and 
prevalence of Eimeria bovis and Eimeria zuernii. 
Three commercial herds and a total of 71 calves, 
aged 48 – 135 days, were included. Treatment 
with a single oral dose of toltrazuril (15 mg/
kg) was given after relocation to common pens 
and one week before expected outbreak of eime-
riosis. The effect of treatment was followed by 
weekly faecal sampling and weighing initially 
and at the end of a study period of 8 weeks. In 
Herd 2 and 3 toltrazuril treated calves gained 
on average 7.95 kg more than placebo treated 
calves (p = 0.007), and both oocyst excretion and 
prevalence of Eimeria spp. were significantly 
reduced the first weeks post treatment. In Herd 
1, by contrast, the farmer made some unfore-
seen changes in the management which entailed 
relocation to large deep-litter pens 3 – 6 weeks 
post treatment. In addition, many calves were 
not treated metaphylactically while few calves 
excreted oocysts when the trial was initiated. 
Thus, no significant difference in weight gain 
was found between toltrazuril and placebo treat-
ed calves (p = 0.523), and the oocyst excretion 
of toltrazuril treated calves was significantly 
higher during week 7 and 8. Significant differ-
ences in faecal scores were observed between 
the herds (p<0.002) but not between treatment 
groups in any of the herds. In conclusion, timing 
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of treatment is crucial for optimal effect of meta-
phylactic toltrazuril treatment on weight gain 
and oocyst excretion.
Introduction
Eimeriosis (coccidiosis) in calves is a ubiquitous 
intestinal infection caused by various Eimeria spe-
cies of which Eimeria züernii and Eimeria bovis are 
considered the most pathogenic (Daugschies and 
Najdrowski, 2005). Bovine eimeriosis is mostly a 
disease of young calves, typically occurring within 
the first six month of age (Taylor and Catchpole 
1994) but all age groups are susceptible although 
the disease is primarily a problem in young ani-
mals reared under intensive production systems.
Experimental infections as well as field studies 
have continuously shown reduced growth rates 
of clinically affected calves (e.g. Stockdale et al. 
1981; Mundt et al. 2005a). However, eimeriosis 
may remain subclinical if the infection pressure is 
low, if the prevalence of highly pathogenic Eimeria 
spp. is low or if immunity has developed due to 
previous infection (Cornelissen et al. 1995); and 
studies have shown that subclinical infection may 
in fact have a higher economic impact than clinical 
eimeriosis due to its wider distribution (Daugschies 
et al. 2007).
Eimeriosis may lead to generalised catarrhal 
enteritis, thickening of the intestinal mucous mem-
branes and in haemorrhagic diarrhoea through 
erosion and destruction of the intestinal mucosa 
(e.g. Friend and Stockdale, 1980). The infection 
may to some extend be controlled by good hygienic 
measures and appropriate farm management pro-
cedures. However, in highly intensive farming 
systems with high stocking rates and frequent relo-
cation of the young calves anticoccidial treatment 
is often necessary to prevent heavy contamination 
of the environment and major economic losses. 
Toltrazuril (Baycox® Bovis) is effective only on 
intracellular stages of Eimeria spp. (Greif G, 
2000), and metaphylactic treatment (treatment in 
the incubation period of the disease) with toltra-
zuril is recommended to allow for a simultaneous 
development of protective immunity along with a 
significant protection against clinical disease and 
oocysts shedding (Epe et al. 2005). 
A recent study found that eimeriosis is highly 
prevalent in Danish dairy herds. In herds with calf 
diarrhoea Eimeria spp. were detected in 60.9 % of 
the individual calves and in 96.2 % of the herds of 
which 88.5 % were positive for E. zuernii and/or 
E. bovis (Enemark et al., 2013). Similar high over-
all prevalences of Eimeria spp. have been found 
in many other studies around the World although 
some European studies have reported remarkably 
lower prevalences of E. zuernii and E. bovis (Cor-
nelissen et al. 1995; Koutny et al. 2012). 
The objective of the current study was to evaluate 
the clinical and parasitological efficacy of metaphy-
lactic treatment with a single oral dose of toltra-
zuril in commercial dairy calf-rearing herds in a 
Danish context.
Material and methods
Study design
The experimental design was a polycentric, place-
bo-controlled, randomised, blinded field study to 
evaluate the effect of metaphylactic treatment with 
Baycox® Bovis or placebo of calves housed together 
in stalls with at least six animals together from 
an approximate age of 2 months. The observation 
period was 8 weeks and the effect parameters 
were bodyweight gain, faecal score and excretion 
of Eimeria oocysts. Following an initial screen-
ing of a large number of dairy herds three herds 
were enrolled in the study. These herds fulfilled 
the inclusion criteria of clinical and laboratory 
confirmed eimeriosis in young calves aged approxi-
mately 2 month in group housing. 
At the start of the trial all calves were weighed 
(weight in), a faecal sample was collected from each 
calf, and the calf was allocated to one of two treat-
ment groups: for each box, calves were stratified 
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according to weight or birth date. Subsequently, 
the first calf was assigned to either treatment 1 or 
treatment 2 by lottery and the following calves 
then alternated between the treatments. Thus, 
the two treatment groups were not separated dur-
ing the study. Bayer HealthCare Denmark kept a 
registration of the assignment of the calves to the 
two groups. This assignment and the identity of 
the two treatments (1 = placebo/Control and 2 = 
Baycox® Bovis/Treat) were not disclosed by Bayer 
HealthCare Denmark until all analyses were com-
pleted. The treatment was a single oral dose of 
3 ml/10 kg body weight of either placebo (full fat 
milk) or Baycox® Bovis Vet 5 % (15 mg/kg). Based 
on pre-screening of the oocyst excretion among 
calves in the herds the treatment was initiated 
one week before expected outbreak of eimeriosis. 
At termination of the experiment all calves were 
weighed again (weight out).
Herds and animals
Herd 1, pre-study information: 
Jersey dairy herd with 480 cows in milking. Calves 
received 3L colostrums shortly after birth and 
within 24 hours post partum they were moved to 
clean, straw-bedded pens with 3 concrete walls of 
1.5m in height in a stable solely used for calves. 
Groups of six calves were housed in each pen and 
remained together in this pen until 16 – 18 weeks 
of age. At this time they were moved to another 
building with two large straw-bedded deep-litter 
pens holding around 40 – 60 calves in each section. 
Although this rearing system should predict eime-
riosis after the movement to the larger deep-litter 
pens, it was a recurrent experience in this herd, 
that approximately 50 % of the calves in each of the 
smaller groups developed clinical eimeriosis with 
diarrhoea, emaciation and unthriftiness. Thus, to 
determine the best time of treatment, faecal sam-
ples from 30 calves, aged 52 to 121 days, were exam-
ined prior to the start of the experiment. Eight of 
these calves excreted more than 1000 oocysts per 
gram of faeces (opg). The youngest of these Eimeria 
positive calves excreted 71,000 opg, of which 10 % 
were E. zuernii, at an age of 68 days. As the pre-
patency period of E. zuernii is 17 – 24 days (Mundt 
et al., 2005a) and based on this screening it was 
thus decided to start metaphylactic treatment at 
approximately 7 weeks of age. With an observation 
period of 8 weeks the study would then be com-
pleted before the calves were transferred to the 
deep-litter pens.
Course of the study: 
Over a period of five weeks 51 calves in nine pens 
were included in the study. Twenty-five calves 
received placebo treatment and 26 calves received 
metaphylactic Baycox® Bovis treatment. The calves 
were approximately 50 days old with a mean body 
weight of around 50 kg when they were enrolled 
in the study (see Table 1 for details). During the 
course of the experiment the number of new-born 
calves exceeded the capacity of the calf stable. 
Consequently, the farmer moved the calves from 
the first two pens to the deep-litter pen already 
three weeks after start when they were aged 
10 – 11 weeks, and calves from the remaining pens 
were moved 4 to 6 weeks post treatment. Since 
all calves were individually ear-tagged this unex-
pected movement of the calves did not have any 
influence on the faecal sampling, but it was evident 
that the infection pressure in the deep-litter pens 
was much higher compared with the smaller pens, 
and many calves developed diarrhoea. Although 
the farmer had agreed to treat all calves with 
clinical signs of eimeriosis he did not do so as he 
feared he would interfere with the experiment. As 
soon as the study veterinarian became aware of 
this problem all calves from the first 7 pens were 
treated with Baycox® Bovis. This was done between 
5 and 9 weeks after the start (i.e. one week after 
the calves were weighed out of the experiment). 
At this time all the calves were also weighed out 
of the study. The calves from the remaining two 
pens were moved two weeks later (6 weeks post 
treatment), at which time they were weighed out 
of the study.
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Herd 2, pre-study information: 
Holstein dairy herd with 230 cows in milking. 
Calves were housed in individual straw-bedded 
outdoor huts from birth to approximately 4 weeks 
of age, and subsequently housed in outdoor huts 
in groups of three. At an age of 8 – 12 weeks, calves 
from three groups were merged and housed in a 
slatted floor pen with bed stalls. Clinical signs of 
eimeriosis appeared in up to 50 % of the calves two 
to three weeks after relocation to the communal 
pen, and massive excretion of Eimeria oocysts were 
detected in these calves.
Course of the study: 
One pen, holding calves (N = 9) aged approximately 
90 days with a mean body weight of about 100 kg 
(see Table 1 for details), was included in the study, 
which started four days after the calves had been 
relocated to the slatted floor pen. Five calves 
received placebo treatment and four calves were 
treated metaphylactically with Baycox® Bovis. 
There were no unforeseen changes in the study 
design, and the calves were weighed out 59 days 
later.
Herd 3, pre-study information: 
Holstein dairy herd with 170 cows in milking. 
Calves were housed in individual straw-bedded 
huts from birth to approximately 8 weeks of age. 
At this age, groups of 9 to 12 calves were moved 
into a calf pen with individual huts and a commu-
nal straw-bedded area. Pre-study samples showed 
massive excretion of Eimeria oocysts two to three 
weeks after relocation into this pen. 
Course of the study: 
One pen holding calves (N = 11) aged around 70 days 
with a body weight of roughly 80 kg (see Table 1 for 
details) was included in the study, which started 
one week after the calves had been moved to the 
communal pen. Due to construction work, the 
calves were slightly older than they would usually 
be at the time of relocation. Six calves received the 
placebo treatment and five calves received meta-
phylactic Baycox® Bovis treatment. There were no 
unforeseen changes in the study design, and the 
calves were weighed out 56 days later.
Faecal examination
Faecal samples were collected at weakly intervals 
and stored at 5oC until analysis within 3 days. The 
oocysts were quantified at the National Veterinary 
Institute by a DANAK accredited modified McMas-
ter technique with a sensitivity of 5 opg (Henriksen 
and Aagaard 1975; Henriksen and Korsholm 1984). 
Eimeria oocysts from all individual samples were 
examined at 400x magnification and identified to 
species level without sporulation using the mor-
phological criteria described by Eckert et al. (1995). 
For each sample the total opg and the relative per-
centage of E. bovis or E. zuernii were determined in 
addition to visual scoring of faecal consistency on a 
scale from one to five (1: normal; 2: soft; 3: liquid; 
4: watery; 5: watery with blood and/or intestinal 
tissue).
Statistical analysis
Body weight
Data were analysed using proc mixed (SAS Inst.). 
All data were analysed in one model: 
Weight out  = + 1*Treat+ 2*Herd1+ 3*Herd2+ 3*Weight in  
Pen was included as a random factor, and the 
effect of Treat, i.e. placebo or Baycox® Bovis, was 
allowed to vary on the pen-level (random slopes 
model). Possible interactions between treatment 
and herd were investigated, and there was a 
significant interaction between herd and treat-
ment. This interaction was further investigated to 
explore treatment effects in the three herds: the 
above mentioned model was simplified to include 
only the intercept and interaction term between 
herd and treatment, start weight and the described 
random effects. A number of contrast statements 
were used to explore differences. 
Oocyst excretion
Dohoo et al. (2003) describe a methodology for 
handling overdispersed data with an excess of 
zeros. Count data are generally assumed to follow 
a Poisson-distribution. One method to account for 
overdispersed count-data is to use a negative bino-
mial regression model. Furthermore, this method 
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can be expanded to the handling of excess zeros. 
Excess zeros are problematic when there are two 
processes by which zero counts can arise. In the 
present study, zeros may have arisen from two dif-
ferent processes: 1) the calf is “truly negative”, i.e. 
no Eimeria oocyst are detected, in which case all 
samples will be negative no matter how many sam-
ples that are examined from the calf; or 2) the calf 
is positive, but the number of oocysts per gram is 
subject to a Poisson distribution.
Zero-inflated models handle the modelling process 
of two distributions, one following a binomial dis-
tribution, whether the calf is positive or not, the 
other being a count-process, following the specified 
distribution for counts. In this case a negative-
binomial distribution. SAS proc NLMIXED (SAS 
9.1) was used for the modelling process. Data were 
modelled for each sampling round simultaneously 
for all three herds except for cases where it was 
obviously irrelevant to model excess zeros. In these 
cases proc genmod (SAS 9.1) was used. When there 
were no positive samples in Treat and Control 
calves in the same sampling round, results from 
that particular herd were not included for that spe-
cific herd. P-values were obtained by a likelihood-
ratio test, comparing models with treatment-effects 
for the binomial distribution, the negative binomial 
distribution, and a baseline model without treat-
ment effect. 
Faecal score
Data were analysed using a cumulative logit model 
assuming proportional odds. Proc genmod (SAS 
9.1) was used. The model included herd and treat-
ment effect as explanatory factors.
Results
Body weight
The mean weight gains of calves treated with 
either Baycox® Bovis or placebo in the different 
herds are shown in Table 1. A positive effect of 
metaphylactic Baycox® Bovis treatment on weight 
gain was shown in Herd 2 and Herd 3, and the com-
bined effect was clearly significant (p = 0.007) cor-
responding to a mean difference in weight gain of 
Table 1 Observational findings for the treatment groups in each of three study herds at the start of the trial.
Variable
Herd 1 Herd 2 Herd 3
Treat Control Treat Control Treat Control
Percentage of calves 
excreting Eimeria spp. 
oocysts
Percentage of calves 
with opg ≥ 500
Percentage of calves 
with E. zuernii and  
E. bovis opg ≥ 500
Percentage of calves 
with faecal score ≥ 3
Body weight (kg) 
(mean, confidence 
intervals)
Age at treatment 
(days) (mean,  
confidence intervals)
8
7.7
0
0
50.11  
(47.49–2.73)
50.63  
(49.14–52.11)
20
12.5
0
37.5
51.46  
(48.50–54.42)
50.57  
(48.80–52.33)
67
0
0
0
105.75  
(76.28–135.22)
89.75  
(76.16–103.3)
25
0
0
0
106.20  
(76.28–135.22)
90.00 
(77.55–102.4)
80
40.0
0
20.0
80.20 
(63.88–96.52)
69.00 
(45.23–92.77)
100
20.0
0
0
80.00 
(63.17–96.83)
69.50 
(52.62–86.38)
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Fig. 1 Mean total oocysts per 
gram of faeces (opg) in calves 
(N=71) from Herd 1–3. Red 
solid lines and circles indicate 
opg values of Baycox® Bovis 
treated calves. Blue dotted 
lines and triangles indicate 
opg values of placebo treated 
calves..
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7.95 kg between Baycox® Bovis and placebo treated 
calves during the study period of eight weeks. In 
contrast, no significant effect of Baycox® Bovis 
treatment was found in Herd 1 as equal weight 
gains were observed in Baycox® Bovis treated 
calves and controls (p = 0.523). In accordance with 
these observations the treatment effect on weight 
in Herd 1 differed significantly from effects in 
Herd 2 and 3 (p = 0.009), whereas the treatment 
effect could be assumed to be equal for Herds 2 
and 3 (p = 0.50). Check for residuals were per-
formed, and revealed no violation of assumptions 
for linear regressions. Residuals were normally 
distributed, and plots showed no violation of equal 
variances for predictors.
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Fig. 2 Herd prevalence (per-
centage) of Eimeria spp. posi-
tive, i.e. excretion of ≥5 oocysts 
per gram (opg), calves (N=71) 
from Herd 1-3 zero to eight 
weeks post treatment. Red 
bars: Baycox® Bovis treated 
calves. Blue bars: placebo 
treated calves.
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Oocyst excretion
Mean excretion of Eimeria spp. oocysts in the treat-
ment groups is presented for each of the three 
study herds in Figure 1, while the percentage of 
calves in which Eimeria spp. oocysts were detected, 
i.e. calves with ≥5 opg, is shown in Figure 2. 
In Herd 1, less than 50 % of the calves excreted 
oocysts at the time of metaphylactic treatment and 
up to week four of the experiment, and only four of 
the 25 placebo treated calves excreted more than 
1000 opg during the first three weeks post treat-
ment. In contrast, all calves (100 %) were excreting 
Eimeria spp. oocysts in Herd 2 by three weeks post 
treatment, and 90 % of the calves in Herd 3 were 
excreting oocysts at the time of Baycox® Bovis 
treatment. 
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Fig. 3 Examples from Herd 1 
of Eimeria spp. oocyst excre-
tion in individual Baycox® 
Bovis (N=6+6) and placebo 
(N=5+6) treated calves, housed 
together in four different 
pens. The vertical lines indicate 
the unpredicted relocation to 
larger deep-litter communal 
pens. X-axis: weeks post treat-
ment. Y-axis: Log oocysts per 
gram (opg). Red solid lines and 
circles indicate opg values of 
Baycox® Bovis treated calves. 
Blue dotted lines and triangles 
indicate opg values of placebo 
treated calves. Values of zero, 
i.e. no oocyst excretion, were 
converted to 0.5 for graphic 
presentation. 
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Corresponding to the distinct differences in preva-
lence of Eimeria spp. oocysts between Herd 1 and 
the other herds, the mean oocyst excretion through-
out the study period showed very different patterns 
in Herd 1 compared to Herd 2 and 3 (Figure 1). 
While the mean oocyst excretion remained high 
and relatively stable around 1000-10,000 opg in 
both Baycox® Bovis and placebo treated calves in 
Herd 1, the oocyst excretion dropped to about zero 
the first two weeks post treatment in Baycox® Bovis 
treated calves in Herd 2 and 3. From week three, the 
oocyst excretion of Baycox® Bovis treated calves in 
Herd 2 and 3 then gradually increased to the same 
level as observed in placebo treated calves in these 
herds. Differences across the treatment groups of 
all herds were significantly different in week 1 and 
3 post treatment (p = 0.004 and 0.005, respectively) 
and close to significant in week 2 (p = 0.13).
 
As concerns the distribution of highly pathogenic 
Eimeria spp. in the herds, the mean oocyst excre-
tion of E. zuernii and E. bovis throughout the first 
5 weeks post treatment was similar in all herds 
with around 1000 opg for each of the species except 
for Baycox® Bovis treated calves in Herd 2 and 3, 
where the oocyst excretion of these species was sig-
nificantly reduced during 5 weeks post treatment 
(p<0.05) after which the excretion increased to 
S209
Protozoa
reach the same level (around 100 opg) as observed 
in the placebo treated calves by the end of the study 
period. Although the excretion levels were low in 
Herd 2 and 3 the prevalence of both species was 
above 90 % in Herd 2, and E. bovis was detected in 
60 % the Baycox® Bovis treated calves and >80 % 
of the placebo treated calves in Herd 3 towards 
the end of the study. In contrast, the prevalence of 
E. bovis only reached approximately 40 % in Herd 1 
while around 50 % of the calves excreted E. zuernii 
despite mean oocyst excretion of around 10,000 opg 
(data not shown).
In Herd 1 a considerable variation in oocyst excre-
tion was observed between the 9 different calf pens. 
Examples of oocyst excretion in individual calves 
exposed to unpredicted relocation to larger deep-
litter communal pens during the study period are 
presented in Figure 3, in which a distinct increase 
in oocyst excretion to values around 10,000 opg is 
evident in Baycox® Bovis treated calves approxi-
mately two weeks after the relocation resulting in 
significantly higher (p ≤ 0.003) oocyst excretion at 
the last two samplings compared to placebo treated 
calves as well as calves in the other study herds. 
In contrast, the oocyst excretion of placebo treated 
calves fluctuated throughout the study period but 
remained at a high level. 
Faecal score
Significant differences in faecal scores were 
observed between the three herds (p < 0.0002) but 
no significant differences in faecal scores were 
found between Baycox® Bovis and placebo treated 
calves (data not shown).
Discussion
Effect of treatment 
In the present study, we report the effect of a single 
oral treatment of dairy calves with Baycox® Bovis, 
15 mg/kg body weight, on parasitological and rel-
evant production parameters. In accordance with 
previous studies (for example Mundt et al. 2005a ) 
the present multicentric field trial demonstrated a 
clear and significant effect of Baycox® Bovis treat-
ment on weight gain and oocyst excretion in Herd 
2 and 3, where the study was executed according to 
the planned design. Over the course of this study, 
i.e. eight weeks, Baycox® Bovis treatment caused 
a mean increased weight gain of 7.97 kg in the 
treated calves compared with calves that received 
placebo. In contrast, there was no significant dif-
ference in weight gain between Baycox® Bovis and 
placebo treated calves in Herd 1, and the mean 
oocyst excretion remained high in both groups 
throughout the whole study period; however, with 
lower oocyst excretion the first weeks post treat-
ment and significantly higher oocyst excretion at 
the end of the trial in Baycox® Bovis treated calves 
compared with the placebo treated calves. 
In Herd 2 and 3, at the time of treatment, one week 
before expected outbreak of clinical eimeriosis, the 
majority of the calves excreted low levels of Eimeria 
spp. oocysts and only one calf had a faeces score of 
≥3. In Herd 1, on the other hand, few calves (<15 %) 
excreted oocysts when the trial was initiated, and 
throughout the first three weeks post treatment 
only four (16 %) of the 25 placebo treated calves 
excreted more than 1000 opg. This suggests that 
the treatment cannot be regarded as metaphylactic 
while the infection was hardly present, and thus 
the calves were not treated during the prepatent 
period. 
Importance of timing 
The overall aim of the present study was to study 
the effect of toltrazuril treatment of calves in 
commercial dairy herds in a Danish context. For 
this reason three herds with a history of clinical 
eimeriosis were selected, and great care was taken 
to predict the expected time of infection in each 
of the herds. Despite all efforts to carry out the 
trial according to a predetermined plan, one of the 
farmers, who provided 51 of the 71 calves in the 
experiment, made some unforeseen changes in 
management routines. This meant that the time 
of exposure to high infection pressure was 
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unpredictable and therefore the calves were not 
treated at the optimal time.
Previous studies have demonstrated the impor-
tance of timing of treatment against eimeriosis. 
Ghanem et al. (2008) showed that metaphylac-
tic toltrazuril treatment (the first day of oocyst 
excretion) reduced the opg and increased the body 
weight gain compared to later treatment timings. 
Likewise, Epe et al. (2005) found that metaphylac-
tic toltrazuril treatment of grazing calves infect-
ed with E. alabamensis resulted in an increased 
weight gain of 7.3 kg compared with therapeutic 
treatment which caused an increased weight gain 
of 3.4 kg compared with placebo treated controls. In 
addition, a study by Jonsson et al. (2011) of immu-
nopathological changes in calves experimentally 
infected with E. bovis and E. zuernii demonstrat-
ed that toltrazuril, 15 mg/kg body weight, given 
14 days post infection reached an efficacy of 99 % 
within three days of treatment and remained above 
this level for six days; however, allowing the devel-
opment of a normal or enhanced immune response 
to infection. In fact, Johnson et al., (2011) showed 
that expression of the genes coding for the anti-
inflammatory cytokines interleukin-2 (IL-2), inter-
leukin-10 (IL-10) in the ileum and tumor necrosis 
factor (TNF) -α in the colon were elevated in tol-
trazuril treated calves. Similarly, Steinfelder et al. 
(2005) showed that toltrazuril treatment of mice 
experimentally infected with E. falciformis termi-
nated the ongoing disease without interfering with 
the establishment of protective immunity against 
challenge infections. 
When the present trial was initiated calves were 
younger in Herd 1, around 50 days of age, compared 
with approximately 80 and 100 days in the other 
two herds; and throughout the first four weeks 
of the study few calves excreted oocysts (Table 1; 
Figure 2). Thus, several of the calves in the 9 sepa-
rate pens included in the study may not have been 
exposed to Eimeria spp. oocysts, and Baycox® Bovis 
treatment may have contributed further to reduc-
tion of the infection pressure, leaving the calves 
vulnerable to the high levels of contamination in 
the deep litter pens that they were moved to at 
various ages from three to six weeks post treatment 
as indicated in Figure 3. Despite the low prevalence 
of eimeriosis in Herd 1 at the time of treatment 
some Eimeria spp. infections with high intensity 
were nevertheless present, and the opg levels in 
Herd 1 were indeed significantly higher (P = 0.003) 
at the last two samplings compared with the other 
herds. Additionally, the placebo treated calves in 
Herd 1 experienced a slightly larger weight gain 
than the Baycox® Bovis treated calves; however, 
this difference was by no means significant. Like-
wise, there were no differences in faecal consist-
ency (data not shown), which altogether indicates 
that no harm was done by treating the calves at 
a time of low prevalence. The results from Herd 
1 are, nevertheless, a clear indication that coccidi-
osis in a herd may vary with changes in manage-
ment, and that any changes in routines may also 
affect the optimal time of metaphylactic treatment 
against coccidiosis. On the other hand, the results 
from Herd 2 and 3 showed that, if given at the 
correct time, the Baycox® Bovis treatment resulted 
Table 2  LSMEANS estimates of weight gain and differences in weight gain 8 weeks post treatment of calves (N=71) from 
three Danish dairy herds treated with Baycox® Bovis (Treat) or placebo (Control). 
Herd
(number of calves)
Treat (kg)
 mean (CI)
Control (kg)
mean (CI) 
Difference (kg)
mean (CI) 
p-value p-value combined
1  (N=51) 26.12 (21.26–30.98) 27.18 (22.38–31.98) -1.06 (-4.31–2.19) 0.523
2  (N=9) 43.6 (29.00–58.23) 33.67 (19.21–48.14) 9.94 (2.21–17.67) 0.020
0.007
3  (N=11) 52.64 (39.30–65.99) 46.31 (33.06–59.57) 6.33 (-0.65–13.30) 0.088
CI: 95 % confidence intervals 
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in significantly higher weight gain in the treated 
calves, but still allowed infection to take place and 
the oocyst excretion to reach the same low level as 
observed in the placebo treated calves towards the 
end of the study period.
Although anticoccidial resistance is known in poul-
try production (Chapman et al., 2013) resistance 
against anticoccidial drugs has not yet been report-
ed in Eimeria spp. of mammals. Nevertheless, the 
possible development of resistance is a course of 
concern considering the widespread distribution 
and huge economic importance of eimeriosis in 
lifestock production (Andrews T, 2008; Lassen and 
Østergaard, 2012). In this context, it is important 
to bear in mind that apparent drug failure does not 
necessarily entail resistance but may simply be due 
to improper timing of the treatment as shown in 
the present study. 
In conclusion, this field study failed to produce 
data on the beneficial effect of Baycox® Bovis in 
Herd 1 due to some unforeseen changes in the 
management while significant results in support 
of a positive effect of metaphylactic treatment 
were observed in Herd 2 and 3. Altogether the 
Baycox® Bovis treated calves in these two herds 
gained on average 7.95 kg more than the placebo 
treated calves over a period of eight weeks. How-
ever, since the total number of calves in Herd 2 and 
3 was rather limited these results must be evalu-
ated with caution. The beneficial effect of Baycox® 
Bovis treatment on oocyst excretion, faeces score 
and weight gain in calves has nevertheless been 
demonstrated convincingly by others (Epe et al., 
2005; Mundt et al, 2005a,b; Veronesi et al., 2011; 
Veronesi et al., 2013). Thus, the main conclusion 
from the present study is that proper timing of 
treatment is crucial. To benefit from Baycox® Bovis 
treatment against eimeriosis the calves should be 
treated metaphylactically i.e. one to two weeks 
post infection (Mundt et al., 2005a), and great care 
should be taken to identify the time of infection/
massive exposure to Eimeria spp. oocysts to allow 
for appropriate timing. If neglected, the treatment 
may be wasted and in worst case, if treated to 
early, the calves might be more vulnerable to mas-
sive infection later in life. Therefore, knowledge of 
farm management is vital in each treatment situa-
tion and accurate diagnostic procedures, preferably 
including quantification and identification of the 
Eimeria species present at farm-level, should be 
employed to determine the typical time of infection 
in each farm.
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